Matrixyl

What it is

Matrixyl is the trade name most commonly associated with palmitoyl pentapeptide-4, a synthetic cosmetic peptide used in topical skin-care products. It should not be confused with Matrixyl 3000, which is a different peptide blend usually described as palmitoyl tripeptide-1 plus palmitoyl tetrapeptide-7. In ingredient lists, the relevant INCI name for the original Matrixyl molecule is generally palmitoyl pentapeptide-4^{[1 –2 ]}.

The biological rationale traces back to research on KTTKS, a five-amino-acid fragment derived from type I procollagen. Katayama and colleagues reported in 1993 that the KTTKS sequence was the minimum sequence needed to stimulate production of extracellular matrix components, including collagen and fibronectin, in cultured mesenchymal cells^{[8 ]}. Cosmetic chemists later attached palmitic acid to KTTKS to create pal-KTTKS, with the goal of improving topical delivery through the lipid-rich stratum corneum^{[2 ,9 –10 ]}.

Mechanistically, Matrixyl is often described as a “signal peptide” or “matrikine.” That language means it is intended to mimic peptide fragments released during extracellular matrix turnover, thereby signaling fibroblast-related matrix activity in laboratory models^{[2 ,8 ,11 ]}. In plain language, the claim is that the molecule resembles a fragment of collagen-processing biology and may influence skin-supporting matrix pathways. Human cosmetic outcomes, however, depend on topical formulation, skin delivery, concentration, and study quality, not mechanism alone.

When used commercially, Matrixyl is applied topically in creams, serums, moisturizers, and eye products^{[2 ]}. Published clinical evidence involves topical cosmetic formulations rather than injection, oral supplementation, or prescription use^{[9 ]}. This section describes studied and marketed routes only; it is not an application or product recommendation.

Regulatory status

Matrixyl is not an FDA-approved prescription drug. In the United States, cosmetic products and ingredients, except most color additives, do not require FDA premarket approval before sale^{[3 ]}. Cosmetic companies are responsible for ensuring products are safe under labeled or customary conditions of use and are not adulterated or misbranded^{[3 ]}.

Cosmetic vs. drug — the claim line

The key regulatory issue is intended use. FDA defines cosmetics as products applied to the body for cleansing, beautifying, promoting attractiveness, or altering appearance^{[3 –4 ]}. FDA states that products intended to treat or prevent disease or to affect the structure or function of the body, including the skin, are drugs even if they also affect appearance^{[4 –5 ]}. FDA’s anti-aging page gives a relevant example: making wrinkles less noticeable by moisturizing is a cosmetic claim, while removing wrinkles or increasing the skin’s collagen production can move a product into drug or device territory^{[5 ]}.

For Matrixyl-containing products, this means language matters. Claims such as “improves the appearance of fine lines” or “helps skin look smoother” are more consistent with cosmetic positioning. Claims that a product “rebuilds collagen,” “repairs damaged tissue,” “treats skin aging,” or “removes wrinkles” may raise drug-claim concerns depending on context^{[4 –6 ]}. FDA also notes that cosmetic labeling must be truthful and not misleading, and that the FTC regulates advertising claims^{[6 ]}.

Compounding and controlled-substance status

Compounding status is not the usual pathway for Matrixyl. This draft did not identify an FDA-approved palmitoyl pentapeptide-4 prescription drug product or a specific 503A/503B compounding pathway for therapeutic use. Injectable or prescription-compounded Matrixyl should therefore be treated as outside the cosmetic evidence base and should receive legal and medical review before any public listing.

Matrixyl is not listed in federal controlled-substance schedules under 21 CFR Part 1308^{[7 ]}. Internationally, the CIR final safety assessment states that the named pentapeptide-4 ingredients are not restricted under European Union cosmetic rules, but product-specific compliance varies by jurisdiction^{[2 ]}. Date of last regulatory update verification: May 6, 2026.

Research summary

The research base for Matrixyl is modest but more concrete than for many cosmetic peptides. It includes one central split-face human study, several in vitro or ex vivo delivery and mechanism studies, and a cosmetic safety assessment. It does not include large independent randomized trials, prescription-drug trials, disease-treatment trials, or long-term clinical outcomes.

Mechanism foundation: Katayama 1993

The foundational mechanism paper is Katayama et al. 1993. The authors dissected a type I procollagen propeptide fragment and identified Lys-Thr-Thr-Lys-Ser, or KTTKS, as the minimum sequence that promoted extracellular matrix production in cultured mesenchymal cells^{[8 ]}. This was not a cosmetic trial, but it provided a plausible basis for later topical cosmetic development.

Lintner and Peschard’s 2000 paper described the broader movement from biologically active peptides to functional skin-care ingredients, including the idea that chemical modification with long-chain fatty acids can make peptide sequences more feasible for topical cosmetics^{[10 ]}. This paper is important historically, but it came from the cosmetic-ingredient development context and should not be treated as independent clinical proof.

Split-face human trial: Robinson 2005

The key human clinical study is Robinson et al. 2005. In that 12-week, double-blind, placebo-controlled, split-face, left-right randomized study, 93 Caucasian women aged 35-55 applied a moisturizer containing 3 ppm pal-KTTKS to one side of the face and the matching moisturizer vehicle to the other^{[9 ]}. The study reported significant improvement versus placebo control in wrinkles and fine lines by quantitative technical analysis and expert-grader image analysis, and the ingredient was described as well tolerated^{[9 ]}. Limitations include the narrow population, split-face cosmetic design, short duration, and the fact that the intervention was a finished moisturizer, not isolated peptide applied under all possible commercial conditions.

Skin penetration: Choi 2014

Skin delivery remains a central question. Choi and colleagues studied KTTKS and pal-KTTKS stability and permeation using hairless mouse skin in vitro^{[11 ]}. Neither KTTKS nor pal-KTTKS was detected in the receptor solution under the study conditions, meaning neither crossed full-thickness skin into the receptor compartment. Pal-KTTKS, however, was detected in the stratum corneum, epidermis, and dermis, while unmodified KTTKS was not detected in any skin layer^{[11 ]}. This supports the rationale for palmitoylation but also shows that delivery is limited and formulation-dependent.

Supporting in vitro studies

Additional in vitro studies support biological plausibility but not clinical certainty. Tsai and colleagues reported that KTTKS promoted type I collagen and TGF-beta-related expression in tendon cells, and Jones and colleagues reported collagen-stimulating effects of a C16-KTTKS peptide amphiphile on human fibroblasts^{[12 –13 ]}. These are laboratory findings and should not be generalized into claims that consumer products rebuild dermal collagen in vivo.

CIR 2024 cosmetic safety assessment

The 2024 CIR final safety assessment reviewed palmitoyl pentapeptide-4 and related pentapeptide ingredients as cosmetic skin-conditioning agents^{[2 ]}. According to 2023 VCRP data summarized by CIR, palmitoyl pentapeptide-4 was reported in 239 cosmetic formulations, including 223 leave-on products; the highest reported leave-on use concentration was 0.0012% in face and neck preparations and eye lotions^{[2 ]}. CIR concluded the reviewed ingredients are safe in cosmetics under present practices of use and concentration, while noting insufficient data to evaluate airbrush delivery systems^{[2 ]}.

Overall, the evidence is strongest for a cosmetic claim that palmitoyl pentapeptide-4-containing moisturizers may improve the appearance of wrinkles and fine lines under studied conditions. Evidence is weaker for broader claims such as “collagen rebuilding,” “skin repair,” “anti-aging treatment,” or results comparable to prescription retinoids, lasers, injectables, or surgery.

Public discourse

Nicole Ruth, MD, board-certified dermatologist, described palmitoyl pentapeptide as a lipid-linked peptide used in cosmetic skin care and framed Matrixyl among better-supported topical peptides. This was consumer beauty commentary, not medical guidance^{[14 ]}.

Whitney Hovenic, MD, dermatologist and surgeon, described Matrixyl as a peptide family that mimics collagen-repair signaling and positioned it as a gentler cosmetic option for people interested in anti-aging skin care^{[15 ]}.

Morgan Rabach, MD, board-certified dermatologist, discussed topical peptides broadly, emphasizing cosmetic routine use and lower photosensitivity concerns compared with some other actives. The article also discussed palmitoyl pentapeptide / Matrixyl 3000, though that terminology may mix the original Matrixyl molecule with later Matrixyl-branded blends^{[16 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Published and reviewed cosmetic safety data suggest palmitoyl pentapeptide-4 is generally well tolerated in topical cosmetic use, but this conclusion applies to cosmetic concentrations and intact-skin use, not injection or medical treatment^{[2 ,9 ,11 ]}.

CIR safety assessment

CIR’s 2024 final assessment reviewed irritation, sensitization, genotoxicity, phototoxicity, and other safety data^{[2 ]}. The panel summarized human patch and repeat-insult patch testing in which formulations containing palmitoyl pentapeptide-4 were not irritating or sensitizing under the tested conditions^{[2 ]}. In Robinson’s 12-week clinical study, the moisturizer containing 3 ppm pal-KTTKS was reported as well tolerated^{[9 ]}.

Formulation matters more than the molecule

The main practical side effects are likely to come from finished formulations rather than the peptide alone. A product containing Matrixyl may also contain fragrance, preservatives, acids, retinoids, botanical extracts, sunscreens, or other ingredients that can irritate sensitive skin. Cosmetic tolerability data for one formulation should not be assumed to apply to every commercial product.

Theoretical concerns

Theoretical concerns include limited skin penetration, peptide degradation in skin, uncertain activity in disrupted skin barriers, and formulation instability^{[2 ,11 ]}. CIR also noted that airbrush delivery systems could not be adequately assessed because of missing exposure data, which is relevant if peptide-containing cosmetics are aerosolized or sprayed^{[2 ]}.

Drug interactions and long-term use

Drug interactions are not established for topical cosmetic palmitoyl pentapeptide-4. There is no robust clinical literature evaluating use after laser resurfacing, chemical peels, microneedling, prescription tretinoin irritation, eczema flares, or active facial dermatitis. Long-term safety data are based mostly on cosmetic use experience and short cosmetic studies rather than multi-year controlled trials.

Available through

Matrixyl is available in the United States as an ingredient in nonprescription cosmetic skin-care products, not as an FDA-approved prescription peptide therapy.

No clinic, telehealth platform, injectable supplier, or research-chemical vendor is listed for Matrixyl as of 2026-05-06. Any future listing should be limited to compliant cosmetic products or retailers after review of ingredient identity, labeling claims, advertising claims, and safety substantiation.

ProPeptideGuide does not link to or endorse injectable Matrixyl, research-chemical Matrixyl, or products marketed with unapproved disease-treatment or drug-like wrinkle-removal claims.